



Ventracor Limited  
 ABN 46 003 180 372  
 126 Greville Street  
 Chatswood NSW 2067  
 Australia  
 T +61 2 9406 3100  
 F +61 2 9406 3101  
 W www.ventracor.com

03032696

7 October 2003

Securities and Exchange Commission  
 Division of Corporate Finance  
 Office of International Corporation Finance  
 450 Fifth Street, NW  
 WASHINGTON DC 20549  
 USA



03032696

SUPPL

Dear Ladies and Gentleman

Re: Ventracor Limited  
File # 82-4630

Ventracor Limited (the "Company") is furnishing herewith information pursuant to Rule 12g3-2(b)(1)(i) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

PROCESSED  
 OCT 29 2003  
 THOMSON  
 FINANCIAL

The attached documents are being furnished with the understanding that they will not be deemed "filed" with the Securities and Exchange Commission or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishing of such documents shall constitute an admission for any purpose that the Company is subject to the Exchange Act.

If you have any questions or comments please call the undersigned at (61) 02 9406 3100.

Very truly yours

*per Andrew Geddes*

Andrew Geddes  
 Corporate Communications

encls

*llw 10/23*



asx announcement

---

### **Ventracor 'Artificial Heart' Pilot Trial Update**

**Sydney, 7 October 2003:** Medical investigators today provided a progress report on the Pilot Trial of the VentrAssist™ 'artificial heart' at The Alfred hospital in Melbourne.

Chief Medical Investigators, Professor Don Esmore and Professor David Kaye, said the second patient to receive an implant of the VentrAssist™ left ventricular assist system (LVAS) had been discharged from hospital.

"Our second patient continues to make an excellent recovery. He was discharged on the 35th day since his implant. This is 18 days earlier than the first patient, who continues to do well at home," Professor Esmore said.

At the discretion of the medical investigators, further implants are expected to be performed at The Alfred hospital shortly.

The Pilot Trial evaluates the safety of the VentrAssist™ in up to 10 patients. Patients who are implanted with the VentrAssist™ system are gravely ill. They are not eligible for a heart transplant and are no longer responding to optimal medical therapy.

While individual outcomes are very important, it is the accumulation of all data on the safety of the device that will decide the outcome of the trial.

*For more information, please contact:*

*Michael Spooner  
Ventracor Limited  
Managing Director & CEO  
02 9406 3088*

*Trisha Lee  
The Alfred  
Public Affairs Manager  
03 9276 2354*